Investing.comDoubao · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 22:12:30·⟳ 抓取 22:17:43 +5m13s·⚡ 决策 10-22 22:27:43 +10m00s·5.0 天前
Vera Therapeutics（VERA.US）TRUTAKNA的ORIGIN 3终期疗效在ASN Kidney Week公布并登NEJM，重申Q4提交sBLA
本条Investing.com稿件（AI生成、且标题错误套用Meta财报）是公司同一新闻稿的延迟改写：ORIGIN 3全部终点阳性的核心结论已于2026-09-15经8-K披露，今日ASN报告/NEJM发表只是旧数据正式呈现，sBLA时间点（Q4 2026提交、2027完全批准）亦为重申，无任何新增金额、指引或监管事实。已处理记录显示股价近5日+16.7%提前抢跑、盘前冲高回落、盘中仅小幅上涨，本催化已被充分定价，做多无edge；数据本身真实阳性支持完全批准，不构成强做空催化，故双向不做。
📄 原文Investing.com↗ 原文
Vera Therapeutics plans FDA filing for IgAN drug in Q4 2026
Meta dips 5% despite earnings beat; capex outlook narrowed amid AI spending surge BRISBANE, Calif. - Vera Therapeutics…
不做 Vera Therapeutics, Inc.（VERA.US）
同一催化14:09 UTC已处理且判定不做；ORIGIN 3阳性核心数据2026-09-15已8-K披露，今日ASN/NEJM无新增临床或监管事实，近5日+16.7%提前抢跑、盘前冲高回落，做多无edge（PRICE_IN）；数据真实阳性、sell-the-news不构成强做空催化，亦不开空。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
TRUTAKNA的ORIGIN 3阳性结果9月15日已8-K公开，今日ASN/NEJM仅为旧数据正式呈现，无新增事实且股价已提前抢跑；真实阳性数据不支持做空，双向不做。
🔎 新鲜度:最早出现 2026-09-15 · 扩散 high · price-in 风险 high ↗
主要风险
- 若后续出现NEJM附带的新长期eGFR斜率亚组或FDA对sBLA的额外标签信号，可能构成新增催化，需另行研判
- sBLA实际提交与FDA完全批准审评仍存在时间与标签不确定性
先例如何影响了这次决策
对本次决策的影响:同事件已在72小时窗口内处理且无新增事实，按查重规则直接AVOID，不再另行检索先例
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 5,493 ms
{"result": "search_processed_events:agent query=`vera origin 3 nejm kidney week proteinuria | vera therapeutics atacocept sbla fda full approval 2027 | vera therapeutics trutakna origin 3 iga nephropathy trial endpoints`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 72.0/72 小时、26297 条本臂决策(完整)，返回 1 条候选。\n• 10-22 14:09 UT
原文全文
展开原文 · 2,035 字
Meta dips 5% despite earnings beat; capex outlook narrowed amid AI spending surge
BRISBANE, Calif. - Vera Therapeutics Inc. (NASDAQ:VERA) announced today that its ORIGIN 3 trial of TRUTAKNA for primary IgA nephropathy met all prespecified endpoints, according to a press release statement.
The final efficacy analysis was presented at the American Society of Nephrology Kidney Week 2026 and published in The New England Journal of Medicine. The trial evaluated TRUTAKNA in adults with primary IgA nephropathy at risk for disease progression.
The study met its primary endpoint of statistically significant proteinuria reduction at 36 weeks. TRUTAKNA also achieved statistically significant reductions in urine-protein to creatinine ratio, galactose-deficient IgA1, and hematuria. The trial showed statistical significance in eGFR change from baseline and annualized slope, as well as risk reduction in composite kidney disease progression events.
The trial enrolled 428 patients, with 214 receiving TRUTAKNA and 214 receiving placebo. Adverse events occurred in 160 TRUTAKNA patients (75%) compared to 167 placebo patients (78%). Serious adverse events occurred in 7% of the TRUTAKNA group versus 15% in the placebo group. Infection rates were 51.4% for TRUTAKNA and 52.3% for placebo. One death occurred in the placebo group and none in the TRUTAKNA group.
TRUTAKNA received FDA accelerated approval to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression. The drug is a BAFF and APRIL inhibitor administered as a 150 mg once-weekly autoinjector.
Vera Therapeutics plans to submit a supplemental Biologics License Application to the FDA in the fourth quarter of 2026, with full approval expected in 2027.
IgA nephropathy affects approximately 2.5 adults per 100,000 worldwide annually. At least 50% of patients may progress to kidney failure or death within 10 to 20 years of diagnosis.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
BRISBANE, Calif. - Vera Therapeutics Inc. (NASDAQ:VERA) announced today that its ORIGIN 3 trial of TRUTAKNA for primary IgA nephropathy met all prespecified endpoints, according to a press release statement.
The final efficacy analysis was presented at the American Society of Nephrology Kidney Week 2026 and published in The New England Journal of Medicine. The trial evaluated TRUTAKNA in adults with primary IgA nephropathy at risk for disease progression.
The study met its primary endpoint of statistically significant proteinuria reduction at 36 weeks. TRUTAKNA also achieved statistically significant reductions in urine-protein to creatinine ratio, galactose-deficient IgA1, and hematuria. The trial showed statistical significance in eGFR change from baseline and annualized slope, as well as risk reduction in composite kidney disease progression events.
The trial enrolled 428 patients, with 214 receiving TRUTAKNA and 214 receiving placebo. Adverse events occurred in 160 TRUTAKNA patients (75%) compared to 167 placebo patients (78%). Serious adverse events occurred in 7% of the TRUTAKNA group versus 15% in the placebo group. Infection rates were 51.4% for TRUTAKNA and 52.3% for placebo. One death occurred in the placebo group and none in the TRUTAKNA group.
TRUTAKNA received FDA accelerated approval to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression. The drug is a BAFF and APRIL inhibitor administered as a 150 mg once-weekly autoinjector.
Vera Therapeutics plans to submit a supplemental Biologics License Application to the FDA in the fourth quarter of 2026, with full approval expected in 2027.
IgA nephropathy affects approximately 2.5 adults per 100,000 worldwide annually. At least 50% of patients may progress to kidney failure or death within 10 to 20 years of diagnosis.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
a943da6389· 2026-10-22 22:27 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前